Effective at the market close on Thursdsay, April 15, 2021, FPRX will be removed from the LifeSci Biotechnology Clinical Trials Index and its values will be redistributed to the remaining index components based on their weights.
On March 4, 2021, Five Prime Therapeutics agreed to be acquired by Amgen for $38.00 per share in cash.
